SANOFI PASTEUR

🇫🇷France

Country: 🇫🇷France

Ownership: Subsidiary

Established: 1990-01-01

Employees: 10K

Market Cap: -

Website: http://www.sanofipasteur.com

Clinical Trials

Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older

Phase 1

Recruiting

Conditions: Human Metapneumovirus Immunization
Respiratory Syncytial Virus Immunization

Interventions: Biological: Placebo
Biological: Investigational hMPV/RSV vaccine
Biological: Investigational RSV vaccine (monovalent)
Biological: Investigational hMPV vaccine (monovalent)
Biological: Licensed RSV Vaccine

First Posted Date: 2024-11-13

Last Posted Date: 2025-05-16

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 1510

Registration Number: NCT06686654

Locations: 🇺🇸
Velocity Clinical Research, Phoenix- Site Number : 8400025, Phoenix, Arizona, United States
🇺🇸
CenExel CNS-Garden Grove- Site Number : 8400017, Garden Grove, California, United States
🇺🇸
National Research Institute - Gardena- Site Number : 8400005, Gardena, California, United States

and more 21 locations

Safety and Immunogenicity of an Investigational Pentavalent Meningococcal ABCYW Vaccine Against Meningococcal Disease in Children, Toddlers, and Infants

Phase 1

Recruiting

Conditions: Meningococcal Immunization
Healthy Volunteers

Interventions: Biological: MenACYW conjugate vaccine
Biological: Pentavalent Meningococcal ABCYW vaccine
Biological: Meningococcal group B vaccine
Drug: Paracetamol
Biological: DTap-HepB-IPV-Hib vaccine
Biological: Pneumococcal 13-valent conjugate vaccine
Biological: Rotavirus vaccine

First Posted Date: 2024-10-17

Last Posted Date: 2025-05-13

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 750

Registration Number: NCT06647407

Locations: 🇩🇰
Investigational Site Number : 2080002, Hvidovre, Denmark
🇨🇿
Investigational Site Number : 2030007, Plzeň, Czechia
🇨🇿
Investigational Site Number : 2030004, Ostrava, Czechia

and more 15 locations

Study to Evaluate Immunogenicity and Safety of a High-Dose Influenza Vaccine in Adults 50 Through 64 Years of Age

Phase 3

Active, not recruiting

Conditions: Influenza

Interventions: Biological: High-Dose trivalent influenza vaccine (Split virion, Inactivated)
Biological: Standard-dose trivalent influenza vaccine (Split virion, Inactivated)

First Posted Date: 2024-10-15

Last Posted Date: 2025-02-14

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 1178

Registration Number: NCT06641180

Locations: 🇺🇸
CenExel CNS- Site Number : 8400005, Los Alamitos, California, United States
🇺🇸
Alliance for Multispeciality Research - Fort Myers- Site Number : 8400019, Fort Myers, Florida, United States
🇺🇸
Research Centers of America - Hollywood- Site Number : 8400010, Hollywood, Florida, United States

and more 17 locations

Study of a Respiratory Syncytial Virus/Human Metapneumovirus/Parainfluenza Virus Type 3 Vaccine Candidate in Adults Aged 60 Years and Older

Phase 1

Active, not recruiting

Conditions: Respiratory Syncytial Virus Infection
Metapneumovirus Infection
Parainfluenzae Virus Infection

Interventions: Biological: RSV/hMPV vaccine
Biological: RSV/hMPV/PIV3 vaccine
Biological: parainfluenza virus type 3 vaccine (PIV3)
Biological: RSV vaccine 1
Biological: RSV vaccine 2

First Posted Date: 2024-09-19

Last Posted Date: 2025-04-04

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 390

Registration Number: NCT06604767

Locations: 🇦🇺
Investigational Site Number : 0360001, Botany, New South Wales, Australia
🇦🇺
Investigational Site Number : 0360009, Brookvale, New South Wales, Australia
🇦🇺
Investigational Site Number : 0360008, Herston, Queensland, Australia

and more 5 locations

Study to Evaluate the Safety and Immune Response of an Investigational Vaccine for the Prevention of RSV (Respiratory Syncytial Virus) and (hMPV) Human Metapneumovirus Infection in Participants Aged 60 to 75 Years

Phase 1

Active, not recruiting

Conditions: RSV Infection
hMPV

Interventions: Biological: RSV/hMPV vaccine dose A1
Biological: RSV/hMPV vaccine dose A3
Biological: RSV/hMPV vaccine dose A2
Biological: RSV/hMPV vaccine dose B1
Biological: RSV/hMPV vaccine dose B2
Biological: RSV/hMPV vaccine dose B3
Biological: RSV/hMPV vaccine dose C1
Biological: RSV/hMPV vaccine dose C2
Biological: RSV/hMPV vaccine dose C3
Biological: RSV/hMPV vaccine dose 1
Biological: RSV/hMPV vaccine dose 2
Biological: RSV/hMPV vaccine dose 3
Biological: Monovalent RSV Vaccine

First Posted Date: 2024-09-03

Last Posted Date: 2025-04-24

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 385

Registration Number: NCT06583031

Locations: 🇦🇺
Site # 0361004, Botany, New South Wales, Australia
🇦🇺
Site # 031001, Brookvale, New South Wales, Australia
🇦🇺
Site # 0361006, Miranda, New South Wales, Australia

and more 3 locations

Study on Biomarkers of Periodontitis and Type 2 Diabetes Mellitus in Males and Females 30 - 70 Years of Age

Not Applicable

Recruiting

Conditions: Periodontal Disease

Interventions: Procedure: Investigational Procedure

First Posted Date: 2024-09-03

Last Posted Date: 2025-05-22

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 300

Registration Number: NCT06582056

Locations: 🇺🇸
University of Iowa - Site Number : 8400002, Iowa City, Iowa, United States
🇺🇸
ADA Forsyth Institute Center for Clinical and Translational Research - Site Number : 8400004, Somerville, Massachusetts, United States
🇺🇸
Stony Brook School of Dental Medicine Periodontics Department- Site Number : 8400001, Stony Brook, New York, United States

and more 1 locations

Study of Influenza Vaccines Containing an Additional H3 Antigen in Healthy Adult Participants 18 to 49 Years of Age and 60 Years of Age and Older

Phase 1

Completed

Conditions: Healthy Volunteers
Influenza

Interventions: Biological: Trivalent-Darwin influenza vaccine
Biological: TIV-2X Darwin influenza vaccine
Biological: Augment-Tasmania influenza vaccine
Biological: Trivalent-Tasmania influenza vaccine

First Posted Date: 2024-07-18

Last Posted Date: 2025-03-12

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 400

Registration Number: NCT06507553

Locations: 🇦🇺
Investigational Site Number : 0360002, Botany, New South Wales, Australia
🇦🇺
Investigational Site Number : 0360010, Brookvale, New South Wales, Australia
🇦🇺
Investigational Site Number : 0360011, Miranda, New South Wales, Australia

and more 7 locations

Co-administration Study of an Investigational Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers

Phase 3

Active, not recruiting

Conditions: RSV Immunization

Interventions: Biological: RSVt vaccine
Biological: Diphtheria, tetanus, pertussis, poliomyelitis , Haemophilus influenzae type b, and hepatitis B vaccine
Biological: Streptococcus pneumoniae vaccine
Biological: Diphtheria, tetanus, pertussis, Haemophilus influenzae type b and poliomyelitis vaccine
Biological: Measles, mumps, and rubella vaccine
Biological: Varicella virus vaccine
Biological: Hepatitis B vaccine
Biological: Rotavirus vaccine
Biological: Placebo

First Posted Date: 2024-05-03

Last Posted Date: 2025-01-14

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 2226

Registration Number: NCT06397768

Locations: 🇲🇽
Investigational Site Number : 4840004, Mexico City, Mexico
🇵🇷
Investigational Site Number : 6300004, Trujillo Alto, Puerto Rico
🇺🇸
South Alabama Medical Clinic- Site Number : 8400065, Grand Bay, Alabama, United States

and more 64 locations

A Study to Investigate the Safety and Immunogenicity of the Quadrivalent Influenza mRNA Vaccines in Adults Aged 18 Years and Above

Phase 1

Active, not recruiting

Conditions: Influenza Immunization

Interventions: Biological: Quadrivalent Influenza mRNA Vaccine MRT5424
Biological: Quadrivalent Influenza Standard Dose Vaccine
Biological: Quadrivalent Influenza High-Dose Vaccine
Biological: Quadrivalent Influenza mRNA Vaccine MRT5429
Biological: Quadrivalent Recombinant Influenza Vaccine
Biological: Quadrivalent Influenza mRNA Vaccine MRT5421

First Posted Date: 2024-04-12

Last Posted Date: 2024-10-09

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 910

Registration Number: NCT06361875

Locations: 🇺🇸
Coastal Carolina Research Center Site Number : 8400014, North Charleston, South Carolina, United States
🇺🇸
Suncoast Research Group, LLC Site Number : 8400015, Miami, Florida, United States
🇺🇸
California Research Foundation Site Number : 8400038, San Diego, California, United States

and more 17 locations

BEYFORTUS™ (Nirsevimab) Effectiveness Against Medically-Attended RSV Events in Infants (BEAR Study)

Active, not recruiting

Conditions: Respiratory Syncytial Virus

Interventions: Other: Nirsevimab

First Posted Date: 2024-03-22

Last Posted Date: 2025-01-14

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 49680

Registration Number: NCT06325332

Locations: 🇺🇸
Kaiser Permanente Northern California: Site number 0001, Oakland, California, United States

Home Terms & Conditions Privacy Policy